Chronic kidney disease (CKD) is one of the most common disabling diseases globally. The main etiopathology of CKD is attributed to progressive renal fibrosis secondary to recurrent renal insults. Anemia is a known complication in CKD patients, associated with higher hospitalization rates and increased mortality risk. CKD-associated anemia (CKD-AA) is either due to true iron deficiency and/or functional iron deficiency anemia. There is new emerging evidence about the effects of erythropoiesis stimulating agents in the treatment of CKD-AA and their role in reversing and preventing kidney fibrosis in the early stages of CKD. This effect potentially provides new scopes in the prevention and treatment of CKD-AA and in decreasing the progression of CKD and the associated long-term complications. Epidemiology, pathophysiology, and treatments of CKD-AA will be discussed.
CITATION STYLE
Habas, E., Rayani, A., Habas, A. M., Akbar, R. A., Khan, F. Y., & Elzouki, A.-N. (2022). Anemia in Chronic Kidney Disease Patients: An Update. Ibnosina Journal of Medicine and Biomedical Sciences, 14(01), 006–011. https://doi.org/10.1055/s-0042-1748774
Mendeley helps you to discover research relevant for your work.